II. Background

  1. No longer available (off market in U.S.) due to hepatotoxicity
  2. Listed for historical reasons only

III. Mechanism

IV. Indications: Non-Valvular Atrial Fibrillation

  1. Warfarin intolerant
  2. Patients with high risk of Intracranial Hemorrhage

V. Advantages

  1. As effective as Warfarin with INR 2-3
  2. Ximelagartan does not require monitoring
  3. Ximelagartan has fewer bleeding complications

VI. Disadvantages

  1. Expensive
  2. Myocardial Ischemia risk
  3. Risk of severe liver toxicity

VII. Dosing

  1. Studies used fixed dose of 36 mg bid

Images: Related links to external sites (from Bing)

Related Studies

Ontology: ximelagatran (C0966370)

Concepts Organic Chemical (T109) , Pharmacologic Substance (T121)
MSH C426686
SnomedCT 415853004
English xi-melagatran, XIMELAGATRAN, ximelagatran [Chemical/Ingredient], Ximelagatran (substance), Ximelagratan, Ximelagratan (substance), Ximelagatran, glycine, N-((1)1-cyclohexyl-2-((2)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester, glycine, N-((1R)1-cyclohexyl-2-((2S)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester, ximelagatran
Spanish ximelagatrán, ximelagatrán (sustancia), ximelagratan, ximelagratan (sustancia)